Drug intelligence / Profile preview

ASKB1202

Development stage: Phase 1
Lead developer: Jiangsu Aosaikang Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ASKB1202 is a biosimilar to bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with receptors. By targeting VEGF, it inhibits angiogenesis (formation of new blood vessels), which is crucial for tumor growth and metastasis. The drug was developed by Jiangsu Aosaikang Pharmaceutical Co. Ltd.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on ASKB1202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASKB1202.

Explore the full profile